UNSPSC 51144502: Pramiracetam sulfate

This classification denotes a neuroprotective agent with the molecular formula C14H27N3O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OP7O7MNS9P, chemically known as 1-pyrrolidineacetamide, n-(2-(bis(1-methylethyl)amino)ethyl)-2-oxo, sulfate (1:1) but more generally known as pramiracetam sulfate, which bears US NIH Compound Identifier 51711. European Medicines Agency schedules Pramiracetam sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04006MIG.

UNSPSC 51144502 Pramiracetam sulfate, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. The three most recent opportunities tagged under this code involve naloxone distribution, direct-to-manufacturer pharmaceutical programs, and generic multi-source pharmaceutical supply — none of which include pramiracetam sulfate as a named product. State and local governments appear to be using this code as a catch-all classification for pharmaceutical procurement rather than as a targeted buy for the specific nootropic compound the code nominates. The actual work being solicited spans pharmaceutical supply agreements, drug deactivation systems, and pharmacy benefit program restructuring across health departments, cooperative purchasing alliances, and public health agencies.

Recent activity clusters in Florida and Minnesota with a multi-state cooperative purchasing component. Seminole County, Florida issued IFB 60459723LAS in June 2026 for annual naloxone and drug deactivation system procurement (1,900 units naloxone, 800 deactivation units) with quarterly deliveries and a July 26, 2023 response deadline. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products spanning participating state and local facilities including Oregon, with a March 26, 2026 proposal deadline and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 as exploratory market intelligence on direct-to-manufacturer pharmaceutical programs without formal competitive timelines. The code's recent activity is driven primarily by state health agencies and cooperative purchasing vehicles rather than individual municipalities or school districts, and the geographic spread remains limited to three states with no indication of broader national activity under this specific code.